CoChat

Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-Hodgkin’s lymphoma

Yan, Zi-Xun, Li, Li, Wang, Wen, OuYang, Bin-Shen, Cheng, Shu, Wang, Li, Wu, Wen, Xu, Peng-Peng, Muftuoglu, Muharrem, Hao, Ming, Yang, Su, Zhang, Mu-Chen, Zheng, Zhong, Li, James, Zhao, Wei-Li · 2019 · Clinical Cancer Research

Published version of a preprint

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

PURPOSE: Anti-CD19 chimeric antigen receptor (CAR) T cells represent a novel immunotherapy and are highly effective in treating relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL). How tumor microenvironment influences clinical response to CAR T therapy remains of great interest. PATIENTS AND METHODS: = 3) cells. Core needle biopsy was performed on tumor samples collected from diffuse large B-cell lymphoma patients on Day -6 (1 day before lymphodepletion) and on Day 11 after CAR T-cell infusion when adequate CAR T-cell expansion was detected. RESULTS: The overall response rate was 100%, with 6 of 9 (66.7%) evaluable patients achieving complete remission. The most common adverse events of grade 3 or higher were neutropenia (10/10, 100%), anemia (3/10, 30%), thrombocytopenia (3/10, 30%), and hypofibrinogenemia (2/10, 20%). Grade 1 cytokine release syndrome occurred in all patients and grade 3 neurotoxicity in 1 patient. The average peak levels of peripheral blood CAR T cells and cytokines were similar in 3 different dose levels, but CAR T cells were significantly higher in patients achieved complete remission on Day 29. Meanwhile, RNA sequencing identified gene expression signatures differentially enriched in complete and partial remission patients. Increased tumor-associated macrophage infiltration was negatively associated with remission status. CONCLUSIONS: JWCAR029 was effective and safe in treating refractory B-NHL. The composition of the tumor microenvironment has a potential impact in CAR T therapy response.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-0101

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Cited by

See all 124

Metadata

Authors
Yan, Z.-X., Li, L., Wang, W., OuYang, B.-S., Cheng, S., Wang, L., Wu, W., Xu, P.-P., Muftuoglu, M., Hao, M., Yang, S., Zhang, M.-C., Zheng, Z., Li, J., & Zhao, W.-L.
Affiliations
  • Shanghai Jiao Tong University (CN)
  • 2JW Therapeutics, Shanghai, China.
  • 3Department of Pathology, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • 5Department of Leukemia, University of Texas - MD Anderson Cancer Center, Houston, Texas.
Corresponding author
Zhao, Wei-Li
Venue
Clinical Cancer Research
Published
2019-12-01
Volume
25
Issue
23
Pages
6995-7003
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2969586911
Cited by
115
References
34
Citations by year
2026: 10 · 2025: 18 · 2024: 16 · 2023: 23 · 2022: 21 · 2021: 13 · 2020: 14
FWCI
5.01
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (81520108003, 81830007, 81600155, 81670716)
  • Chang Jiang Scholars Program, Shanghai Commission of Science and Technology (16JC1405800)
  • Shanghai Municipal Education Commission Gaofeng Clinical Medicine Grant (20152206, 20152208)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
CD19 CAR T cells, CAR T-cell therapy, B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, relapsed/refractory lymphoma, tumor microenvironment, tumor-associated macrophages, dose escalation, complete remission, cytokine release syndrome, CAR-T cell expansion, gene expression signatures, lymphocyte depletion
MeSH terms
Adult, Antibodies, Monoclonal, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Immunotherapy, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Immunotherapy, Adoptive, Lymphoma, B-Cell, Salvage Therapy, Antigens, CD19, Drug Resistance, Neoplasm, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-Hodgkin’s lymphoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-0101
The paper
Yan, Z.-X., Li, L., Wang, W., OuYang, B.-S., Cheng, S., Wang, L., Wu, W., Xu, P.-P., Muftuoglu, M., Hao, M., Yang, S., Zhang, M.-C., Zheng, Z., Li, J., & Zhao, W.-L. (2019). Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-Hodgkin’s lymphoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-0101

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.